COREY SHUMATE: Open Payments
NPI 1245758580 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$623 in 5 payments from 4 companies in 2025. Trend: 2023 $365 · 2024 $117 · 2025 $623
Food & beverage: $623
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $287 |
| Teva Pharmaceuticals USA, Inc. | 1 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $117 |
| Lilly USA, LLC | 1 | $100 |
Products named: INGREZZA, UZEDY, CAPLYTA, ZEPBOUND.
Industry payments across IL — which companies pay providers there.
